Filing Flows › Companies › Sarepta Therapeutics › Earnings quality
Sarepta Therapeutics earnings quality score
How much of the reported profit is backed by cash, and how many markers of managed earnings the filings show
Score66 / 100 · grade B · rank 522 of 1027
Sarepta Therapeutics (SRPT) scores 66 of 100 for earnings quality, grade B: rank 522 of 1027 companies and 54 of 126 in health. It loses the most points on adjusted earnings 427% below GAAP, discretionary accruals of -6.7% of assets (modified Jones), larger than most, Montier C-score 1 of 5 checks failed. It earns full or near-full marks for profit about as variable as cash flow (smoothness 1.65).
What earned and lost points
| Component | What the filings show | Points | Of |
|---|---|---|---|
| Accruals | accruals of -13.9% of assets, lower than 91% of companies (profit backed by cash) | 24 | 27 |
| Dechow F-score | Dechow F-score 1.27 (above normal) | 16 | 20 |
| Montier C-score | Montier C-score 1 of 5 checks failed | 16 | 20 |
| Discretionary accruals | discretionary accruals of -6.7% of assets (modified Jones), larger than most | 3 | 13 |
| Non-GAAP gap | adjusted earnings 427% below GAAP | 0 | 13 |
| Earnings smoothness | profit about as variable as cash flow (smoothness 1.65) | 7 | 7 |
How the score is built
Eight published measures, each scored against the whole universe or on its own scale and weighted: accruals 20, discretionary accruals 10, Beneish M 15, Dechow F 15, Montier C 15, Piotroski F 10, the non-GAAP gap 10, smoothness 5. A measure that cannot be computed (Beneish for a bank, say) drops out and the rest is rescaled, so every company is scored on what applies to it.
Every company ranked → The full quality workbench, live → Sarepta Therapeutics: cash flow →
Computed from the companies’ own XBRL filings (latest fiscal year) by published formulas; a statistical screen, not an audit or an accusation. A low score means the reported profit shows more of the markers of managed or low-quality earnings than its peers. Not investment advice.